A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Taejoon Pharmaceutical Co., Ltd.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
* Male or female, age 19 or over
* Written informed consent to participate in the trial
You may not be if
* Any other Galucoma except POAG(ex, Closed anterior chamber angle, angle-closure glaucoma)
* Any laser or ocular surgery within 3months prior screening
* Use of contact lenses
* Known reactive airways disease
* Any condition limiting patient's ability to participate in the trial
Clareo Health | A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
